X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-04 | BLTE | Belite Bio, Inc | Lin Yu-Hsin | CEO | S - Sale | $190.00 | -100,435 | 70,134 | -59% | -$19,082,549 | |||||
| M | 2026-09-04 | BLTE | Belite Bio, Inc | Chuang Hao-Yuan | CFO | S - Sale | $189.98 | -67,395 | 26,038 | -72% | -$12,803,528 | |||||
| M | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.33 | -259,837 | 3,885,115 | -6% | -$1,905,768 | |||||
| M | 2026-09-04 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.33 | -259,837 | 3,885,115 | -6% | -$1,905,768 | |||||
| M | 2026-09-04 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $68.88 | +9,976 | 551,876 | +2% | +$687,160 | |||||
| M | 2026-07-16 | CVSI | Cv Sciences, Inc. | Cheever Charlie E III | 10% | P - Purchase | $0.02 | +5,740,816 | 26,648,711 | +27% | +$114,816 | |||||
2026-09-01 | CYBN | Cybin Inc. | So Eric H. L. | Exec Chair | P - Purchase | $11.81 | +95,000 | 4,318,630 | +2% | +$1,121,475 | ||||||
| DM | 2026-09-04 | HRMY | Harmony Biosciences Holdings, Inc. | Budur Kumar | CHIEF MEDICAL OFFICER | S - Sale+OE | $42.80 | -33,954 | 13,115 | -72% | -$1,453,169 | |||||
| D | 2026-09-08 | ASND | Ascendis Pharma A/S | Bodenhoff Mads | SVP, PAO | S - Sale+OE | $270.19 | -3,000 | 0 | -100% | -$810,570 | |||||
| D | 2026-09-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $499.03 | -9,500 | 668,728 | -1% | -$4,740,795 | |||||
2026-09-04 | NAMS | Newamsterdam Pharma Co N.V. | Smither John W | Dir | S - Sale | $25.32 | -1,600 | 8,760 | -15% | -$40,512 | ||||||
2026-09-04 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $79.96 | -1,689 | 13,427 | -11% | -$135,052 | ||||||
2026-09-08 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $45.61 | -8,210 | 561,435 | -1% | -$374,498 | ||||||
| D | 2026-09-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $42.92 | -871 | 59,882 | -1% | -$37,383 | |||||
| D | 2026-09-08 | URGN | Urogen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $42.54 | -1,519 | 53,141 | -3% | -$64,618 | |||||
| D | 2026-09-08 | PHVS | Pharvaris N.V. | Lu Peng | Pres | S - Sale+OE | $40.68 | -15,000 | 65,179 | -19% | -$610,134 | |||||
2026-08-31 | CYBN | Cybin Inc. | Glavine Paul | Chief Growth Officer | P - Purchase | $11.59 | +90,000 | 4,302,193 | +2% | +$1,042,677 | ||||||
| M | 2026-09-03 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.04 | -16,119 | 634,427 | -2% | -$97,323 | |||||
| D | 2026-08-31 | ATHE | Alterity Therapeutics Ltd | Marks Peter Ashley | Dir | P - Purchase | $0.50 | +47,620 | 191,340 | +33% | +$23,810 | |||||
2026-09-03 | LGND | Ligand Pharmaceuticals Inc | Reardon Andrew | CLO, Secretary | S - Sale | $286.09 | -5,000 | 36,514 | -12% | -$1,430,434 | ||||||
| D | 2026-09-08 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.46 | -2,500 | 17,217 | -13% | -$41,142 | |||||
2026-09-03 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.78 | +900,000 | 6,524,151 | +16% | +$1,604,160 | ||||||
| D | 2026-09-08 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $75.46 | -3,500 | 153,902 | -2% | -$264,110 | |||||
| D | 2026-09-04 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $489.20 | -9,500 | 668,728 | -1% | -$4,647,354 | |||||
| M | 2026-09-04 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $23.42 | -1,085 | 152,897 | -1% | -$25,408 | |||||
| M | 2026-09-04 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $22.95 | -5,035 | 162,564 | -3% | -$115,546 | |||||
2026-09-08 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $18.88 | -5,658 | 429,507 | -1% | -$106,823 | ||||||
2026-09-03 | IRD | Opus Genetics, Inc. | Gagnon Robert E. | CFO | S - Sale | $4.54 | -28,000 | 556,375 | -5% | -$127,212 | ||||||
2026-09-03 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | SVP, Chief Accounting Officer | S - Sale | $13.99 | -161 | 69,146 | 0% | -$2,252 | ||||||
2026-09-02 | EOLS | Evolus, Inc. | Moatazedi David | See Remarks | S - Sale | $9.04 | -105,108 | 499,592 | -17% | -$950,019 | ||||||
| M | 2026-08-31 | CATX | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC | 10% | S - Sale | $3.14 | -113,914 | 11,563,425 | -1% | -$357,184 | |||||
| D | 2026-09-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $487.54 | -9,500 | 668,728 | -1% | -$4,631,619 | |||||
| D | 2026-09-02 | TRAX | First Tracks Biotherapeutics, Inc. | Ware J. Anthony | Dir | S - Sale+OE | $44.78 | -39,265 | 15,660 | -71% | -$1,758,145 | |||||
2026-09-01 | ANTX | An2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | S - Sale | $5.53 | -272 | 66,311 | 0% | -$1,504 | ||||||
2026-09-04 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +9,800 | 9,397,056 | 0% | +$479 | ||||||
| D | 2026-09-02 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $35.12 | -18,500 | 235,244 | -7% | -$649,642 | |||||
| D | 2026-09-02 | PVLA | Palvella Therapeutics, Inc. | Kiritsy Christopher P | Dir | S - Sale+OE | $157.00 | -313 | 250 | -56% | -$49,141 | |||||
| D | 2026-09-02 | JNJ | Johnson & Johnson | Schmid Timothy | EVP, WW Chair, MedTech | S - Sale+OE | $274.74 | -33,597 | 26,251 | -56% | -$9,230,440 | |||||
2026-09-02 | TAK | Takeda Pharmaceutical Co Ltd | Plump Andrew Stewart | Pres, R, D | S - Sale | $18.49 | -116,191 | 912,034 | -11% | -$2,148,372 | ||||||
| DM | 2026-09-01 | SYRE | Spyre Therapeutics, Inc. | King-Jones Heidy | See Remarks | S - Sale+OE | $87.35 | -28,399 | 2,845 | -91% | -$2,480,529 | |||||
| DM | 2026-09-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $88.75 | -25,732 | 79,762 | -24% | -$2,283,821 | |||||
2026-09-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $87.29 | -15,000 | 552,540 | -3% | -$1,309,410 | ||||||
| D | 2026-09-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.43 | -25,000 | 119,655 | -17% | -$2,860,737 | |||||
| D | 2026-09-02 | CORT | Corcept Therapeutics Inc | Vieira Roberto Wandenkolk | Pres, Oncology | S - Sale+OE | $110.76 | -58,333 | 4,242 | -93% | -$6,460,766 | |||||
2026-09-02 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | S - Sale | $23.63 | -3,187 | 273,871 | -1% | -$75,306 | ||||||
| M | 2026-09-01 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $7.14 | -86,482 | 4,144,952 | -2% | -$617,379 | |||||
| M | 2026-09-01 | TRDA | Entrada Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $7.14 | -86,482 | 4,144,952 | -2% | -$617,379 | |||||
| D | 2026-09-03 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $208.65 | -10,000 | 0 | -100% | -$2,086,500 | |||||
| D | 2026-09-01 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale+OE | $37.83 | -3,333 | 96,412 | -3% | -$126,078 | |||||
2026-09-02 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale | $100.00 | -658 | 616 | -52% | -$65,800 | ||||||
| D | 2026-09-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $98.68 | -30,000 | 381,940 | -7% | -$2,960,401 | |||||
2026-09-02 | BMRN | Biomarin Pharmaceutical Inc | Davis George Eric | EVP, GC | S - Sale | $66.28 | -17,557 | 61,003 | -22% | -$1,163,748 | ||||||
2026-09-03 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $48.01 | -2,034 | 223,422 | -1% | -$97,652 | ||||||
2026-09-02 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.47 | +27,000 | 962,500 | +3% | +$255,739 | ||||||
2026-09-02 | ABT | Abbott Laboratories | McCoy John A. Jr. | VP, CONTROLLER | S - Sale | $109.54 | -27 | 24,608 | 0% | -$2,958 | ||||||
| M | 2026-09-01 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $80.15 | -54,496 | 13,445 | -80% | -$4,367,944 | |||||
2026-09-01 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale | $355.86 | -132 | 97,929 | 0% | -$46,974 | ||||||
| M | 2026-09-02 | REGN | Regeneron Pharmaceuticals, Inc. | McCourt Marion | EVP Commercial | S - Sale | $853.56 | -2,346 | 12,222 | -16% | -$2,002,458 | |||||
| D | 2026-09-02 | REGN | Regeneron Pharmaceuticals, Inc. | Guarini Kathryn | Dir | S - Sale+OE | $850.00 | -400 | 603 | -40% | -$340,000 | |||||
| D | 2026-09-03 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $482.03 | -8,300 | 45,172 | -16% | -$4,000,836 | |||||
| D | 2026-09-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $493.46 | -9,500 | 668,728 | -1% | -$4,687,841 | |||||
2026-09-01 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale | $67.76 | -274 | 117,308 | 0% | -$18,566 | ||||||
| D | 2026-09-01 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $106.41 | -23,124 | 4,000 | -85% | -$2,460,690 | |||||
| M | 2026-09-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $69.21 | +1,683 | 541,900 | 0% | +$116,488 | |||||
2026-09-02 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $66.37 | -642 | 118,016 | -1% | -$42,610 | ||||||
2026-09-01 | GENB | Generate Biomedicines, Inc. | Arnold Frances | Dir | S - Sale | $16.00 | -1,000 | 463,944 | 0% | -$16,002 | ||||||
| D | 2026-09-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $22.37 | -27,000 | 115,743 | -19% | -$603,909 | |||||
2026-08-31 | CAMP | Camp4 Therapeutics Corp | Gold Kelly | CFO | P - Purchase | $3.96 | +10,000 | 86,467 | +13% | +$39,600 | ||||||
| D | 2026-09-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $25.76 | -5,787 | 9,110 | -39% | -$149,072 | |||||
2026-08-31 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.74 | -10,257 | 318,480 | -3% | -$28,112 | ||||||
2026-08-31 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.67 | -34,463 | 1,226,427 | -3% | -$91,899 | ||||||
2026-08-31 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.75 | -9,683 | 258,688 | -4% | -$26,658 | ||||||
2026-09-01 | ANTX | An2 Therapeutics, Inc. | Fitzpatrick Margaret M | Dir | P - Purchase | $5.53 | +2,098 | 10,708 | +24% | +$11,602 | ||||||
| D | 2026-08-28 | CDT | Cdt Equity Inc. | Regan Andrew | CEO | S - Sale+OE | $0.00 | -290 | 5,699,306 | 0% | -$0 | |||||
| M | 2026-08-31 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.79 | +770,333 | 5,624,151 | +16% | +$1,381,750 | |||||
2026-09-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $250.13 | -6,000 | 351,875 | -2% | -$1,500,780 | ||||||
2026-09-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $2.02 | -19 | 23,782 | 0% | -$38 | ||||||
| D | 2026-09-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $514.09 | -9,500 | 668,728 | -1% | -$4,883,839 | |||||
2026-08-31 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $10.24 | -1,099 | 366,529 | 0% | -$11,254 | ||||||
| M | 2025-05-30 | EMMA | Emmaus Life Sciences, Inc. | Lee Willis C | CEO | P - Purchase | $0.03 | +530,767 | 1,326,485 | +67% | +$18,126 | |||||
2026-09-02 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +3,000 | 9,387,256 | 0% | +$147 | ||||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Carter Denise P. | COO | P - Purchase | $4.88 | +20,490 | 37,709 | +119% | +$99,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Myers Michael | CEO | P - Purchase | $4.88 | +20,490 | 37,713 | +119% | +$99,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Lawlor Sally Bridget | CFO | P - Purchase | $4.88 | +10,244 | 10,684 | >999% | +$49,991 | |||||
| D | 2026-08-31 | QNRX | Quoin Pharmaceuticals, Ltd. | Culverwell Anthony James | Dir | P - Purchase | $4.88 | +6,146 | 40,364 | +18% | +$29,992 | |||||
| D | 2026-08-28 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $35.77 | -200,000 | 1,599,154 | -11% | -$7,153,393 | |||||
| D | 2026-09-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $46.99 | -9,000 | 65,389 | -12% | -$422,874 | |||||
| D | 2026-09-01 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | COO | S - Sale+OE | $91.82 | -5,000 | 236,384 | -2% | -$459,101 | |||||
| D | 2026-09-01 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | CEO | S - Sale+OE | $91.83 | -75,000 | 925,580 | -7% | -$6,887,484 | |||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.49 | -15,000 | 1,664,208 | -1% | -$127,308 | ||||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $8.49 | -16,666 | 1,127,796 | -1% | -$141,434 | ||||||
2026-09-01 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.50 | -5,000 | 1,356,053 | 0% | -$42,500 | ||||||
2026-08-31 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale | $72.80 | -2,850 | 171,843 | -2% | -$207,480 | ||||||
| D | 2026-08-31 | NBP | Novabridge Biosciences | Xu Cong Claire | EVP, Clinical Development | S - Sale+OE | $0.79 | -3,282 | 304,201 | -1% | -$2,593 | |||||
2026-09-01 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.86 | -15,000 | 62,065 | -19% | -$87,966 | ||||||
| D | 2026-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.47 | -1,452 | 117,227 | -1% | -$36,982 | |||||
2026-09-01 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $71.48 | -5,000 | 10,784 | -32% | -$357,400 | ||||||
| DM | 2026-08-28 | OMER | Omeros Corp | Cancelmo Peter B | VP, GC | S - Sale+OE | $18.59 | -50,000 | 200 | -100% | -$929,668 | |||||
| D | 2026-08-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -679 | 51,776 | -1% | -$13,580 | |||||
| D | 2026-08-31 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $511.09 | -9,500 | 668,728 | -1% | -$4,855,312 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |